Egypt has over 118 million people, making it the most populous country in the Arab world and the third largest in Africa. The Egypt healthcare system is in the middle of several concurrent shifts: a new universal insurance law rolling out governorate by governorate, digital health infrastructure being built largely from scratch, and a pharmaceutical sector that is already the largest on the continent by volume. For organisations working in clinical development, market access, or public health across North Africa, the structure of healthcare in Egypt and the state of its data infrastructure matter directly.
Egypt's Healthcare System at a Glance
Egypt's health sector is shaped by a mix of public provision, private enterprise, and out-of-pocket spending. The National Health Strategy 2024-2030 and the broader Egypt Vision 2030 set the direction: reduce premature NCD deaths by a third, hit 85 percent insurance coverage by 2026/27, and renovate 520 healthcare facilities. The Ministry of Health and Population (MOHP) alone operates over 5,300 primary healthcare facilities and 521 hospitals. The governmental hospital sector holds approximately 83,000 beds (CAPMAS, 2021), while the private sector runs over 1,100 hospitals with approximately 33,000 beds. According to World Bank data, the country offers about 1.4 hospital beds per 1,000 people, well below the global average of 2.9.
Health spending is low. In fiscal year 2025-26, the national health budget reached 245 billion Egyptian pounds, about 1.1 percent of GDP. The 2014 constitution mandates a minimum of 3 percent of GDP for health, but actual allocations have sat between 1 and 1.4 percent since 2021. Total current health expenditure including private spending was roughly 4.6 percent of GDP in 2024, still below the WHO recommendation of 5 to 6 percent for countries pursuing universal coverage.
Life expectancy at birth is approximately 72 years overall, with females averaging 74.4 years and males 69.4 years according to Egypt's Central Agency for Public Mobilisation and Statistics (CAPMAS). Egypt has about 0.67 physicians per 1,000 inhabitants, compared with a global average of 1.71. The nursing workforce is similarly stretched. Approximately 207,000 nurses serve a population of over 118 million, a ratio of about 1.9 nurses and midwives per 1,000 people (World Bank, 2018), well below the WHO's SDG-era threshold of 4.45 doctors, nurses, and midwives combined per 1,000. The Ministry of Health has acknowledged a shortage of at least 44,000 nurses, though that estimate dates from when the population was closer to 80 million, so the actual gap is almost certainly larger now. Roughly 90 percent of Egypt's nurses hold technical secondary diplomas rather than university degrees, and a 2025 BMC Nursing study found that 25.9 percent of recent graduates were actively considering leaving the profession, citing low salaries (averaging about 5,500 Egyptian pounds per month) and limited career progression.
Universal Health Insurance Law: Progress and Challenges
The Universal Health Insurance (UHI) Law No. 2 of 2018 is Egypt's biggest health reform in decades. The law aims to replace the fragmented insurance system, which previously covered fewer than 60 percent of Egyptians, with a single mandatory scheme funded through payroll contributions, government subsidies, and tobacco taxes.
Implementation is proceeding in phases. The first phase launched in Port Said in 2019 and has since expanded to six governorates: Port Said, Ismailia, Luxor, Suez, South Sinai, and Aswan. By early 2025, this first phase covered 5.1 million beneficiaries, backed by investments of 28.5 billion Egyptian pounds in facility upgrades and staffing.
The second phase targets five additional governorates with 12 million beneficiaries and a 20 billion Egyptian pound investment allocation. Presidential directives have pushed for nationwide completion by 2027, ahead of the original 2032 target. Significant obstacles remain. Covering the remaining 27 governorates requires sustained fiscal commitment that current budget trends do not clearly support. Many facilities outside the pilot governorates need renovation, equipment, and trained staff before they can meet UHI accreditation standards. And registering and collecting contributions from Egypt's large informal workforce is a logistical problem that no one has fully solved.
The reform's success will determine whether Egypt can reduce the crushing burden of out-of-pocket payments, which currently account for roughly 62 percent of total health expenditure, according to a systematic review published in the Journal of the Egyptian Public Health Association.
Public vs Private Healthcare Delivery
Hospitals in Egypt are split across multiple government bodies. The MOHP runs the largest share of public facilities, but university hospitals, military medical services, and the Health Insurance Organization each operate their own networks. These bodies do not coordinate well, and quality of care varies widely between them.
The private sector has grown rapidly, particularly in Cairo, Alexandria, and other major cities. Private hospitals tend to be smaller (averaging 29 beds compared with 125 in public hospitals) but are often better equipped and staffed. Major private hospital groups such as Cleopatra Hospitals Group and Saudi German Hospitals operate multi-site networks catering to middle- and upper-income patients.
For most Egyptians, public facilities remain the primary point of care. The gap between public and private quality produces a familiar pattern: patients who can afford it seek private care or travel abroad, while lower-income populations use overcrowded public hospitals with limited resources. Nigeria and South Africa have similar two-track systems, though the specific mix of public and private provision in each country reflects different policy choices and histories.
Disease Burden and Epidemiological Profile
Egypt's disease burden has shifted decisively toward noncommunicable diseases (NCDs), which the WHO estimates account for 82 percent of all deaths and 67 percent of premature deaths in the country. Cardiovascular disease, diabetes, cancer, and chronic respiratory conditions are the leading causes of mortality.
The most notable public health success story is the campaign against hepatitis C virus (HCV). Egypt historically had one of the highest HCV prevalence rates in the world, a legacy of mass schistosomiasis treatment campaigns in the mid-twentieth century that inadvertently spread the virus through reused needles. The resulting health burden exceeded 40,000 deaths annually and cost an estimated 3.6 billion US dollars in healthcare spending.
In 2018, the government launched the 100 Million Healthy Lives campaign, which screened over 60 million people for HCV and noncommunicable diseases across all 27 governorates. More than 4 million patients received direct-acting antiviral treatment. HCV incidence dropped from 300 per 100,000 in 2014 to 9 per 100,000 by 2022, putting Egypt on track to be the first country to eliminate hepatitis C. The campaign also generated a large screening dataset covering NCDs, a resource that, if properly structured and linked, could support population health analytics across North Africa. Kapsule has been tracking how such large-scale screening programmes across the continent create opportunities for real-world evidence generation.
Obesity and diabetes are growing problems. Egypt's National Health Strategy 2024-2030 lists obesity reduction and diabetes management as priority targets. The pattern is consistent with what other middle-income African economies are seeing as diets and lifestyles change.
Digital Health and EMR Adoption
Digital health in Egypt is early-stage. As of October 2024, only 314 hospitals had implemented electronic health record (EHR) systems, a small fraction of the country's total facility count. Paper-based records are still the norm in most public facilities, which limits data aggregation, clinical decision support, and health system monitoring.
The government is pushing to change this. In November 2025, Egypt launched its National Digital Health Strategy 2025-2029, which targets:
- Establish standardised EHR systems across UHI-accredited facilities
- Enable data-driven decision-making at the facility, governorate, and national levels
- Expand telemedicine services, particularly for underserved rural populations
- Strengthen data governance, privacy protections, and interoperability standards
The Egyptian Drug Authority (EDA) has also advanced digital infrastructure for clinical research. In January 2026, the EDA launched a digital platform for protocol management and clinical trials, replacing paper-based submissions with an electronic workflow aligned with international standards.
Rwanda and Kenya are further along the EHR adoption curve. Egypt's larger population and more established pharmaceutical sector create different scaling problems. The gap between policy ambition and facility-level implementation is still wide.
Clinical Research Capacity and Pharma Manufacturing
Egypt is one of Africa's most active clinical trial destinations. Over 10,500 clinical trials have been registered on ClinicalTrials.gov with Egypt as a study site, according to a 2024 analysis. The volume is a function of the country's large patient population, established research institutions, and improving regulatory capacity.
The Egyptian Drug Authority earned the WHO's Maturity Level 3 (ML3) designation for medicines regulation, making Egypt the first African nation to achieve ML3 status for both medicines and vaccine oversight. In practice, this means a regulatory environment that can support multinational trials and faster product approvals.
On the manufacturing side, Egypt's pharmaceutical market reached 6.5 billion US dollars in 2024 and is projected to grow at a compound annual rate of 8.7 percent through 2033. The country is the largest pharmaceutical manufacturer in Africa by volume, with domestic companies supplying a significant share of the regional market.
VACSERA, the state-owned biologics manufacturer, operates 11 manufacturing plants producing 70 pharmaceutical products including vaccines, antisera, and blood products. Egypt was selected as the headquarters for the North Africa Biomanufacturing Center, a regional initiative for vaccine and biologics production. The National Strategy for Vaccine Manufacturing Localization 2024-2030 aims to reduce import dependency and build Egypt into a continental biologics hub.
Regulatory maturity, manufacturing scale, and clinical research infrastructure together make Egypt a relevant market for pharmaceutical companies evaluating North African expansion. But the value of this infrastructure depends on the quality and accessibility of underlying health data, and that is where significant investment is still needed.
Opportunities for Data-Driven Health Innovation
Egypt has scale and structural gaps in roughly equal measure, and that combination creates real opportunities for data-driven approaches. The 100 Million Healthy Lives campaign showed the country can execute population-level health programmes. Translating screening data into longitudinal, research-grade datasets is the harder part, and it requires sustained investment in data infrastructure.
What works in Egypt's favour: over 118 million people with a young demographic profile, which means the patient volumes needed for statistically powered real-world evidence studies. The EDA's ML3 status and new digital trial management platform lower barriers for international sponsors. A 6.5 billion dollar domestic pharma market with strong generic manufacturing creates demand for market intelligence and pharmacovigilance data. And as the universal insurance system scales, it will generate claims and encounter data across a growing number of accredited facilities.
The constraints are the same ones that slow data-driven work across the continent: fragmented record-keeping, limited interoperability between systems, and governance frameworks for responsible data sharing that are still being written. Platforms like Kapsule, which aggregate de-identified health records with ethics approvals and standardised data pipelines, offer one model for addressing these constraints at scale.
Egypt's combination of universal coverage ambition, early-stage digital health investment, and existing pharmaceutical manufacturing capacity makes it one of the most important healthcare markets in Africa over the next decade.
Kapsule provides access to structured, de-identified health records from over three million patient encounters across East and West Africa, with standing ethics approvals in Rwanda, Kenya, Uganda, Nigeria, and Ghana. Contact our team to discuss how Egyptian health data and North African market intelligence can support your clinical development and commercial strategy.
This article is intended for informational purposes only and does not constitute legal, medical, or regulatory advice. Readers should obtain independent professional counsel for their specific circumstances.